Literature DB >> 23239049

Prevalence and incidence of pituitary adenomas: a population based study in Malta.

Mark Gruppetta1, Cecilia Mercieca, Josanne Vassallo.   

Abstract

Epidemiological data is important to correctly quantify the extent of disease and needed health care resources. The aim of the study was to establish the prevalence and incidence of pituitary adenomas (PAs) in the same well defined population, with in-depth analysis of the various subtypes. The design involved a retrospective cross-sectional analysis of PA patients diagnosed prior to 31 July 2011 for prevalence estimates and those diagnosed between July 2000 and July 2011 for incidence estimation. A thorough search for patients with PAs was carried out in central hospital registries including outpatients departments, surgical registries, radiological department and specialty clinic databases. Prevalence rates/100,000 and Standardised incidence ratios (SIR)/100,000/year were worked out. The respective prevalence rates and SIR for PAs overall were 75.7/100,000, and 4.27/100,000/year, for Prolactinomas 35.0/100,000 and 2.05/100,000/year, for nonfunctioning PA 25.9/100,000 and 1.79/100,000/year and for GH-secreting PAs 12.5/100,000 and 0.31/100,000/year. The overall prevalence for macroadenomas was 32.8/100,000 and SIR was 1.49/100,000/year. The prevalence rate in males for PAs overall was 46.3/100,000 and SIR was 2.08/100,000/year and in females 104.8/100,000 and SIR was 6.58/100,000/year. Females had a lower proportion of macroadenomas than males (29.5 vs. 75.0%; P < 0.001) and macroadenomas tended to present at a later age compared to microadenomas (48 vs. 34.5; P < 0.001). The highest SIR was reached in the 30-39 age group at 7.42/100,000/year. Our data confirm the considerable disease burden that PAs bear on health care resources. Males and females have similar prevalence and SIR rates for macroadenomas but there is a significant increase in SIR in females of child bearing age compared to males. These observations may have important implications in terms of the economic burden and need for early intervention.

Entities:  

Mesh:

Year:  2013        PMID: 23239049     DOI: 10.1007/s11102-012-0454-0

Source DB:  PubMed          Journal:  Pituitary        ISSN: 1386-341X            Impact factor:   4.107


  22 in total

1.  Incidence of pituitary adenomas in Northern Finland in 1992-2007.

Authors:  Antti Raappana; John Koivukangas; Tapani Ebeling; Tapio Pirilä
Journal:  J Clin Endocrinol Metab       Date:  2010-06-09       Impact factor: 5.958

2.  Pituitary adenomas in Sweden between 1958 and 1991: incidence, survival, and mortality.

Authors:  B Nilsson; E Gustavasson-Kadaka; B A Bengtsson; B Jonsson
Journal:  J Clin Endocrinol Metab       Date:  2000-04       Impact factor: 5.958

3.  Quality of life is decreased after treatment for nonfunctioning pituitary macroadenoma.

Authors:  O M Dekkers; A A van der Klaauw; A M Pereira; N R Biermasz; P J Honkoop; F Roelfsema; J W A Smit; J A Romijn
Journal:  J Clin Endocrinol Metab       Date:  2006-06-20       Impact factor: 5.958

4.  Impaired quality of life of patients with acromegaly: control of GH/IGF-I excess improves psychological subscale appearance.

Authors:  Maria P Matta; Elisabeth Couture; Laurent Cazals; Delphine Vezzosi; Antoine Bennet; Philippe Caron
Journal:  Eur J Endocrinol       Date:  2008-03       Impact factor: 6.664

Review 5.  The epidemiology and genetics of pituitary adenomas.

Authors:  Adrian F Daly; Maria A Tichomirowa; Albert Beckers
Journal:  Best Pract Res Clin Endocrinol Metab       Date:  2009-10       Impact factor: 4.690

6.  Age-related and gender-related occurrence of pituitary adenomas.

Authors:  T Mindermann; C B Wilson
Journal:  Clin Endocrinol (Oxf)       Date:  1994-09       Impact factor: 3.478

7.  Prevalence of pituitary adenomas: a community-based, cross-sectional study in Banbury (Oxfordshire, UK).

Authors:  Alberto Fernandez; Niki Karavitaki; John A H Wass
Journal:  Clin Endocrinol (Oxf)       Date:  2009-07-24       Impact factor: 3.478

8.  Subclinical pituitary microadenomas.

Authors:  M G Siqueira; A L Guembarovski
Journal:  Surg Neurol       Date:  1984-08

9.  Pituitary gland MR: a comparative study of healthy volunteers and patients with microadenomas.

Authors:  B W Chong; W Kucharczyk; W Singer; S George
Journal:  AJNR Am J Neuroradiol       Date:  1994-04       Impact factor: 3.825

10.  Prevalence and presentation of hyperprolactinaemia in patients with "functionless" pituitary tumours.

Authors:  S Franks; J D Nabarro
Journal:  Lancet       Date:  1977-04-09       Impact factor: 79.321

View more
  45 in total

1.  Do race and age vary in non-malignant central nervous system tumor incidences in the United States?

Authors:  Haley Gittleman; David J Cote; Quinn T Ostrom; Carol Kruchko; Timothy R Smith; Elizabeth B Claus; Jill S Barnholtz-Sloan
Journal:  J Neurooncol       Date:  2017-06-30       Impact factor: 4.130

2.  Expression of cell cycle regulators and biomarkers of proliferation and regrowth in human pituitary adenomas.

Authors:  Mark Gruppetta; Robert Formosa; Sharon Falzon; Sabrina Ariff Scicluna; Edward Falzon; James Degeatano; Josanne Vassallo
Journal:  Pituitary       Date:  2017-06       Impact factor: 4.107

3.  Epidemiology of acromegaly in Italy: analysis from a large longitudinal primary care database.

Authors:  Federico Gatto; Gianluca Trifirò; Francesco Lapi; Francesco Cocchiara; Claudia Campana; Carlotta Dell'Aquila; Carmen Ferrajolo; Marica Arvigo; Claudio Cricelli; Massimo Giusti; Diego Ferone
Journal:  Endocrine       Date:  2018-05-24       Impact factor: 3.633

Review 4.  Epidemiology, clinical presentation and diagnosis of non-functioning pituitary adenomas.

Authors:  Georgia Ntali; John A Wass
Journal:  Pituitary       Date:  2018-04       Impact factor: 4.107

5.  Complete evaluation of pituitary tumours in a single tertiary care institution.

Authors:  Dimitrios Askitis; Damianos Tsitlakidis; Nicolle Müller; Albrecht Waschke; Gunter Wolf; Ulrich Alfons Müller; Christof Kloos
Journal:  Endocrine       Date:  2018-03-12       Impact factor: 3.633

Review 6.  The optimal numerosity of the referral population of pituitary tumors centers of excellence (PTCOE): A surgical perspective.

Authors:  Pietro Mortini; Gianluca Nocera; Francesca Roncelli; Marco Losa; Anna Maria Formenti; Andrea Giustina
Journal:  Rev Endocr Metab Disord       Date:  2020-12       Impact factor: 6.514

Review 7.  Epidemiology and etiopathogenesis of pituitary adenomas.

Authors:  Elena D Aflorei; Márta Korbonits
Journal:  J Neurooncol       Date:  2014-01-31       Impact factor: 4.130

Review 8.  Prolactinomas and menopause: any changes in management?

Authors:  Yona Greenman
Journal:  Pituitary       Date:  2020-02       Impact factor: 4.107

Review 9.  Giant pituitary adenoma: histological types, clinical features and therapeutic approaches.

Authors:  Pedro Iglesias; Víctor Rodríguez Berrocal; Juan José Díez
Journal:  Endocrine       Date:  2018-06-16       Impact factor: 3.633

Review 10.  Endocrine disrupting chemicals: exposure, effects on human health, mechanism of action, models for testing and strategies for prevention.

Authors:  Bayram Yilmaz; Hakan Terekeci; Suleyman Sandal; Fahrettin Kelestimur
Journal:  Rev Endocr Metab Disord       Date:  2020-03       Impact factor: 6.514

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.